Search Results
The default setting for search results displays All Content. If you prefer to see recent content only, please adjust the date filter.
Filter your results:
Types
Topics
12 Results Found
Department of Labor releases proposed rule on transparency of PBM fee disclosures
The Department of Labor has issued a proposed rule to improve transparency of fees collected by pharmacy benefit managers.
HHS OIG releases bulletin on direct-to-consumer drug sales, RFI on need for regulatory changes
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell prescription drugs to patients with federal health care program coverage at lower costs without violating the Anti-Kickback Statute.
CMS announces drugs selected for third round of drug price negotiations
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations.
Senate introduces bill requiring price disclosures on ads for prescription drugs
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that would require price disclosures on advertisements for prescription drugs. The bill would help ensure that consumers are able to make more informed decisions on prescription drugs.
Reminder: CMS hosting webinar Oct. 21 on price transparency machine-readable file 2025 requirements
The Centers for Medicare & Medicaid Services Oct. 21 will host a webinar on meeting its new hospital price transparency requirements becoming effective Jan. 1.
Senate Aging Committee holds hearing on transparency, health care costs
The AHA submitted a statement July 11 for a Senate Special Committee on Aging hearing on health care transparency and lowering health care costs.
Mark Cuban Lays Out More Details about How He’s Disrupting Drug Pricing
Learn how Mark Cuban is disrupting drug pricing and making waves in the pharmaceutical industry. Find out more about his Cost Plus Drugs company and its collaborations with payers and pharmacists.
3 Ways GLP-1 Drugs Could Impact Your Hospital’s Future
Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand. Overall, the GLP-1 market is expected to experience annual growth exceeding 20% and will hit $133 billion worldwide by 2030, according to a MarketWatch report from February.
Cost-Plus Drug Pricing Models Gain Momentum, but Will They Last?
CVS Health plans to launch its CVS CostVantage and CVS Caremark TrueCost programs in 2025. CostVantage will define the drug cost and related reimbursement with contracted PBMs and payers, CVS noted in a statement.
Will Startup PBMs Drive Drug Price Transparency?
The Purchaser Business Group on Health (PBGH), a coalition of about 40 large private and public employers including Walmart, Disney, Costco and Microsoft, recently launched EmsanaRx, a nonprofit PBM. Meanwhile, billionaire Mark Cuban’s Cost Plus Drug Company is another PBM that launched recently.